PL3377518T3 - Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii - Google Patents

Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii

Info

Publication number
PL3377518T3
PL3377518T3 PL16810138.4T PL16810138T PL3377518T3 PL 3377518 T3 PL3377518 T3 PL 3377518T3 PL 16810138 T PL16810138 T PL 16810138T PL 3377518 T3 PL3377518 T3 PL 3377518T3
Authority
PL
Poland
Prior art keywords
bacteria engineered
hyperphenylalaninemia
reduce
reduce hyperphenylalaninemia
engineered
Prior art date
Application number
PL16810138.4T
Other languages
English (en)
Inventor
Dean Falb
Vincent M. Isabella
Jonathan W. Kotula
Paul F. Miller
Sarah ROWE
Yves Millet
Original Assignee
Synlogic Operating Company, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2016/032562 external-priority patent/WO2016183531A1/en
Application filed by Synlogic Operating Company, Inc. filed Critical Synlogic Operating Company, Inc.
Publication of PL3377518T3 publication Critical patent/PL3377518T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/88—Lyases (4.)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
    • C07K14/245—Escherichia (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/527—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving lyase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y104/00—Oxidoreductases acting on the CH-NH2 group of donors (1.4)
    • C12Y104/03—Oxidoreductases acting on the CH-NH2 group of donors (1.4) with oxygen as acceptor (1.4.3)
    • C12Y104/03002—L-Amino-acid oxidase (1.4.3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y403/00—Carbon-nitrogen lyases (4.3)
    • C12Y403/01—Ammonia-lyases (4.3.1)
    • C12Y403/01024—Phenylalanine ammonia-lyase (4.3.1.24)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/988—Lyases (4.), e.g. aldolases, heparinase, enolases, fumarase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PL16810138.4T 2015-11-16 2016-11-16 Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii PL3377518T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562256052P 2015-11-16 2015-11-16
PCT/US2016/032562 WO2016183531A1 (en) 2015-05-13 2016-05-13 Bacteria engineered to reduce hyperphenylalaninemia
PCT/US2016/062369 WO2017087580A1 (en) 2015-11-16 2016-11-16 Bacteria engineered to reduce hyperphenylalaninemia

Publications (1)

Publication Number Publication Date
PL3377518T3 true PL3377518T3 (pl) 2022-09-26

Family

ID=58717781

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16810138.4T PL3377518T3 (pl) 2015-11-16 2016-11-16 Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii

Country Status (8)

Country Link
US (2) US11618894B2 (pl)
EP (2) EP4095150A1 (pl)
JP (4) JP6993970B2 (pl)
AU (2) AU2016356684C1 (pl)
CA (1) CA3005451A1 (pl)
ES (1) ES2925049T3 (pl)
PL (1) PL3377518T3 (pl)
WO (1) WO2017087580A1 (pl)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3377518T3 (pl) * 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
IL271085B2 (en) 2017-06-21 2024-07-01 Synlogic Operating Co Inc Bacteria to treat disorders
KR20220003030A (ko) 2019-04-29 2022-01-07 신로직 오퍼레이팅 컴퍼니, 인코포레이티드 살아 있는 세포 계수 기술에 의한 유전적으로 조작된 미생물의 계수
WO2020247594A1 (en) 2019-06-04 2020-12-10 Cocoon Biotech Inc. Silk-based products, formulations, and methods of use
US20220268782A1 (en) 2019-07-15 2022-08-25 Inserm (Institut National De La Santé Eat De La Recherche Médicale) Methods for predicting and treating cardiac dysfunction
CN110643585B (zh) * 2019-11-08 2021-09-03 江南大学 一种利用氨基酸脱氨酶生产α-酮-β-甲基正戊酸的方法
CN113493796B (zh) * 2020-03-18 2023-05-30 苏州优信合生技术有限公司 苯丙酮尿症治疗用益生菌工程菌株的构建方法与应用
WO2022120028A2 (en) 2020-12-02 2022-06-09 Synlogic Operating Company, Inc. Engineered microorganisms
CN112501098B (zh) * 2020-12-11 2023-01-03 上海陶宇晟生物技术有限责任公司 具有降解苯丙氨酸能力的工程益生菌
CN112662607A (zh) * 2021-01-07 2021-04-16 上海陶宇晟生物技术有限责任公司 具备表面展示苯丙氨酸解氨酶的工程益生菌
WO2023044479A1 (en) * 2021-09-17 2023-03-23 Synlogic Operating Company, Inc. Methods for reducing hyperphenylalaninemia
CN113969292B (zh) * 2021-11-15 2023-07-07 山东第一医科大学(山东省医学科学院) 治疗苯丙酮尿症的工程益生菌及其构建方法与应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9107305D0 (en) 1991-04-08 1991-05-22 Unilever Plc Probiotic
CN1154845A (zh) 1996-09-09 1997-07-23 首都医学院附属北京红十字朝阳医院 能表达活性苯丙氨酸脱氨酶的基因工程菌口服制剂
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6203797B1 (en) 1998-01-06 2001-03-20 Stephen C. Perry Dietary supplement and method for use as a probiotic, for alleviating the symptons associated with irritable bowel syndrome
WO2000032748A1 (en) 1998-12-02 2000-06-08 Trustees Of Boston University Gene networks for control of gene expression
EP1034787A1 (en) 1999-03-11 2000-09-13 Société des Produits Nestlé S.A. Lactobacillus strains preventing diarrhea caused by pathogenic bacteria
AUPQ899700A0 (en) 2000-07-25 2000-08-17 Borody, Thomas Julius Probiotic recolonisation therapy
ATE331789T1 (de) 2001-05-03 2006-07-15 Vlaams Interuniv Inst Biotech Selbsterhaltender lactococcus stamm
US7314974B2 (en) * 2002-02-21 2008-01-01 Monsanto Technology, Llc Expression of microbial proteins in plants for production of plants with improved properties
US7731976B2 (en) 2003-08-29 2010-06-08 Cobb And Company, Llp Treatment of irritable bowel syndrome using probiotic composition
JP4452914B2 (ja) 2003-09-08 2010-04-21 味の素株式会社 新規トランスポータタンパク質
AU2005321630A1 (en) * 2004-07-02 2006-07-06 Metanomics Gmbh Process for the production of fine chemicals
GB0501540D0 (en) 2005-01-25 2005-03-02 Univ Leeds Controlled production and delivery of biologically active agents by gut bacteria
CA2614769A1 (en) * 2005-03-10 2006-09-21 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
CA2653967A1 (en) 2006-06-02 2008-10-02 Verenium Corporation Lyase enzymes, nucleic acids encoding them and methods for making and using them
TW200819540A (en) 2006-07-11 2008-05-01 Genelux Corp Methods and compositions for detection of microorganisms and cells and treatment of diseases and disorders
US9084434B2 (en) 2006-09-27 2015-07-21 Little Calumet Holdings Llc Probiotic oral dosage forms
US20100297249A1 (en) 2007-07-05 2010-11-25 North-West University Enhancement of the efficacy of therapeutic proteins
CN101586111B (zh) 2008-05-22 2012-03-07 北京三元基因工程有限公司 一种活性乳酸乳球菌制品的制备方法
EP2344626B1 (en) 2008-09-29 2017-03-29 Intrexon Actobiotics NV Reduced colonization of microbes at the mucosa
JP6013195B2 (ja) * 2010-03-02 2016-10-25 ルネサンス バイオサイエンス コーポレーション アクリルアミドの産生を最小化するための微生物の機能強化
US8129170B1 (en) 2010-12-06 2012-03-06 E.I. Du Pont De Nemours And Company Recombinant bacteria having the ability to metabolize sucrose
EP2655624B1 (en) 2010-12-23 2017-11-29 Biogen MA Inc. Linker peptides and polypeptides comprising same
US9017961B2 (en) 2012-03-05 2015-04-28 E.I. Du Pont De Nemours And Company Recombinant bacteria comprising novel sucrose transporters
FR2990699B1 (fr) 2012-05-21 2016-02-05 Agronomique Inst Nat Rech Cassettes d'expression procaryotes regulees par le stress
DK2864491T3 (en) * 2012-06-22 2018-12-17 Phytogene Inc Enzymes and methods for styrene synthesis
WO2014018832A1 (en) 2012-07-27 2014-01-30 University Of North Texas Genetically modified probiotic for the treatment of phenylketonuria (pku) disease
US20150246085A1 (en) * 2012-11-01 2015-09-03 The Sydney Children's Hospital Network (Randwick & Westmead) Genetically-Modified Probiotic for Treatment of Phenylketonuria
AU2013358998B2 (en) 2012-12-13 2019-04-18 Massachusetts Institute Of Technology Recombinase-based logic and memory systems
EP2964240B1 (en) 2013-03-07 2018-10-24 The General Hospital Corporation Compositions and methods for bacterial delivery of polypeptides
US9688967B2 (en) * 2014-12-05 2017-06-27 Synlogic, Inc. Bacteria engineered to treat diseases associated with hyperammonemia
WO2016183532A1 (en) 2015-05-13 2016-11-17 Synlogic, Inc. Bacteria engineered to treat a disease or disorder
ES2881384T3 (es) * 2015-05-13 2021-11-29 Synlogic Operating Co Inc Bacterias manipuladas para reducir la hiperfenilalaninemia
CA2988981A1 (en) * 2015-06-10 2016-12-15 Synlogic, Inc. Bacteria engineered to treat disorders involving the catabolism of a branched chain amino acid
WO2016210373A2 (en) 2015-06-24 2016-12-29 Synlogic, Inc. Recombinant bacteria engineered for biosafety, pharmaceutical compositions, and methods of use thereof
US20170216370A1 (en) * 2015-07-31 2017-08-03 Synlogic, Inc. Bacteria engineered to treat disorders involving propionate catabolism
PL3377518T3 (pl) * 2015-11-16 2022-09-26 Synlogic Operating Company, Inc. Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii

Also Published As

Publication number Publication date
EP3377518B1 (en) 2022-04-13
WO2017087580A1 (en) 2017-05-26
US11618894B2 (en) 2023-04-04
JP7494345B2 (ja) 2024-06-03
JP2018535678A (ja) 2018-12-06
JP2024112925A (ja) 2024-08-21
JP6993970B2 (ja) 2022-02-15
EP4095150A1 (en) 2022-11-30
JP7245312B2 (ja) 2023-03-23
JP2023085294A (ja) 2023-06-20
ES2925049T3 (es) 2022-10-13
EP3377518A1 (en) 2018-09-26
AU2022201838A1 (en) 2022-04-07
AU2016356684A1 (en) 2018-05-31
US20240076645A1 (en) 2024-03-07
JP2022046527A (ja) 2022-03-23
AU2016356684C1 (en) 2022-11-10
US20180320161A1 (en) 2018-11-08
AU2016356684B2 (en) 2021-12-16
CA3005451A1 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
ZA201707678B (en) Bacteria engineered to reduce hyperphenylalaninemia
IL278150A (en) A transgenic bacterium for the treatment of diseases related to hyperammonemia
HK1257676A1 (zh) 工程化 crispr-cas 9 核酸酶
HK1252666A1 (zh) 針對cd40的抗體
PL3377518T3 (pl) Bakterie modyfikowane do celów zmniejszenia hiperfenyloalaninemii
GB201514489D0 (en) Hyperphenylalaninemia
GB2541833B (en) Improvements to implant surfaces
HK1252613A1 (zh) 作為cot調節劑的6-氨基-喹啉-3-腈
GB201409541D0 (en) Probiotic Bacteria
GB201408039D0 (en) Culture dish
GB201515330D0 (en) Bioreactor condenser
GB201519450D0 (en) Novel treatment
GB201514420D0 (en) Bioreactor
GB2538045B (en) Improvements to letter-plates
GB201514734D0 (en) Mechanical bioreactor
HK1253094A1 (zh) 多肽組合物
GB201520827D0 (en) Bioreactor
GB2522473B (en) Improvements to windposts
GB201517420D0 (en) Improvements to bedpans
GB201518810D0 (en) Bioreactor
GB201517290D0 (en) Bioreactor
GB201521028D0 (en) Improvements to Li-fi
GB2520781B (en) Improvements to hydro-turbines
GB201501181D0 (en) Ready-to-assemble pond
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny